Clinical testing of the first implantable device combining cardiac contractility modulation with cardioversion/defibrillation is underway: https://cle.clinic/3PjlPcC
Cleveland Clinic’s Post
More Relevant Posts
-
Thermedical Successfully Completes Feasibility Study for Treating Cardiac Arrhythmias Using Pulsed Field Ablation in Combination with SERF Ablation WESTON, Mass.--(BUSINESS WIRE)-- #Durablate--Thermedical®, a developer of advanced thermal-ablation systems to treat ventricular arrhythmias, announced today that it has completed a feasibility study utilizing Pulsed Field Ablation (PFA) therapy in combination with its SERF Ablation System and Durablate® Catheter for treating ventricular tachycardia (VT). VT is an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide. via Business Wire Health: Medical Devices News April 23, 2024 at 04:01PM
To view or add a comment, sign in
-
Congratulations to Johnson & Johnson for Shockwave obtention. I share my first Shockwave case here In 2020 at Institute Arnault Tzanck A 49 years old patient with an inferior myocardial infarction involving an acute occlusion of the right coronary artery. Percutaneous coronary intervention was complicated by balloon’s stent rupture and stent under-deployment into a calcification seen in stent boost enhancement. After failed attempts to post dilate the under deployed stent with: - non-compliant - super high pressure - and cutting balloons --> Shockwave balloon which corrected the stent under deployment after 20 therapies delivered only. This case reports highlights the importance to have Shockwave technology available in heart catheterization laboratory. #Shockwave #Institutarnaulttzanck #JohnsonandJohnson #cardioetvous #ECC_Congres #CongresACTIF #GRCICardio
To view or add a comment, sign in
-
-
The #SMARTtrial data makes a difference for women. With its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore how the Evolut™ #TAVR valve design delivers superior outcomes for women with small annuli vs. SAPIEN platform at 1 year¹: https://bit.ly/4eb8a31 Risk Info: https://bit.ly/4aKlCI1 TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
To view or add a comment, sign in
-
Changes in myocardial native T1 may be used in the clinical setting to track treatment response in cardiac light-chain amyloidosis. https://ja.ma/48bIWhP
Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 Mapping
jamanetwork.com
To view or add a comment, sign in
-
CONCLUSIVE real-time remote patient Cardiac & Vitals diagnostics, with early detection, deterioration, diagnosis & adverse event prediction, patients treated sooner. Supporting the HSE, NHS & Private healthcare.
𝗥𝗲𝗱𝘂𝗰𝗲 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗖𝗼𝘀𝘁𝘀 Implantable loop recorders often detect, within the first couple of weeks after being fitted, the cardiac arrhythmias clinicians were trying to capture evidence for before deciding the correct treatment. The cost of an invasive implanted loop recorder can cost upwards of £2000, with loop device, implantation, removal, clinic times, etc costs. The reusable SmartCardia sensor, at a fraction of the cost of loop recorders, can give clinicians continuous conclusive 7-leads of very low noise ECG, transmitted live in Real-time, delivering cardiac arrhythmia evidence much sooner. Clinicians can see the full disclosure from the time the monitor was fitted to the present time. Vital signs are also transmitted giving a much more diagnostic view of the patient. www.smartcardia.com contact@smartcardia.com +44 (0) 74000 28 317
To view or add a comment, sign in
-
-
This review addresses the rationale for left ventriculoplasty, presents the prior surgical and percutaneous attempts in the field, provides an overview of the novel transcatheter left ventriculoplasty devices and their respective trials, and highlights potential challenges associated with establishing such device-based therapies in the armamentarium against heart failure. #EIJBestOf https://ow.ly/yt8t50QEo07
To view or add a comment, sign in
-
-
The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/3w6d6oI Risk Info: https://bit.ly/44rllbl TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
See the Late-Breaking SMART Trial Data
medtronic.com
To view or add a comment, sign in
-
CT cardiac: Prospective gated means scan will happen on 75% or 45% heart rate only, we can't do recon on other heart rates. We get only one set of sequence, patient get low radiation Retrospective gated means scan will happen 25% to 80% we can do any recons different heart rate systolic and dialostic, patient will get high radiation dose.
To view or add a comment, sign in
-
ICMs are increasingly used for cardiac rhythm diagnosis with expanding indications. Dr Jorge Toquero Ramos is sharing his view about benefits of the LUX-Dx™ ICM System vs conventional monitoring when it comes to the understanding different types of unexplained syncopes as well as the detection of AF after a stroke. It is time to expect more from your ICM. Learn more here: https://lnkd.in/dNWXzGj8 #BSCEMEA #ICM #CardiacMonitor
To view or add a comment, sign in
-
The #SMARTtrial 1-year outcomes are here! Due to its focus on patients with small annuli, 87% of those enrolled in this late-breaking trial were women. Explore this revolutionary data and see how Evolut™ #TAVR makes a big difference for women with #AorticStenosis¹: https://bit.ly/43NEsw2 Risk Info: https://bit.ly/4aKWBwY TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker. 1. Herrmann H, et al. Self-expanding Versus Balloon-expandable Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli: Primary Outcomes From the Randomized SMART Trial. Presented at ACC: April 2024.
See the Late-Breaking SMART Trial Data
medtronic.com
To view or add a comment, sign in